Acute cerebellar toxicity induced by high dose of cytarabine (HiDAC): A case report.
Hamid RahmaniMojan RadmehrMolouk HadjibabaieMohammad SolduzianPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
Cytarabine is a pyrimidine analogue that is used for the treatment of acute myeloid leukemia at different doses. Standard doses of cytarabine are used for induction therapy, while high doses are used for post-remission (consolidation) and relapsed/refractory treatment. One of the major side effects of its high doses is acute cerebellar toxicity occurring in 10 to 25% of patients. We report a case that developed this side effect after receiving two doses of high-dose cytarabine. The patient's symptoms improved after withholding the drug. Thereafter, the patient tolerated treatment continuation with lower doses.
Keyphrases
- respiratory failure
- high dose
- acute myeloid leukemia
- low dose
- stem cell transplantation
- allogeneic hematopoietic stem cell transplantation
- oxidative stress
- end stage renal disease
- case report
- stem cells
- chronic kidney disease
- rheumatoid arthritis
- acute lymphoblastic leukemia
- emergency department
- depressive symptoms
- diffuse large b cell lymphoma
- peritoneal dialysis
- bone marrow
- liver failure
- hepatitis b virus
- drug induced
- acute respiratory distress syndrome
- sleep quality
- replacement therapy
- electronic health record